{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-220788","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.099015+00:00","generated_at":"2026-05-17T05:33:22.409583+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Atossa Therapeutics posts updated corporate presentation; no specific financial details provided","bullets":["Filed as Exhibit 99.1 on September 26, 2025, but presentation content not included in this filing text.","No new financial figures, pipeline milestones, or guidance changes are extractable from the available text.","Ticker ATOS; company is a clinical-stage biotech focused on breast cancer treatments.","Investors would need to view the actual presentation to assess any material updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-220788","json":"https://secwatch.observer/filing/0001193125-25-220788.json","markdown":"https://secwatch.observer/filing/0001193125-25-220788.md","text":"https://secwatch.observer/filing/0001193125-25-220788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312525220788/0001193125-25-220788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312525220788/atos-20250926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:33:22.409583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}